寡转移性肾细胞癌的 SAbR
2026年8月7日 更新者:Raquibul Hannan、University of Texas Southwestern Medical Center
SAbR 治疗寡转移性肾细胞癌的 II 期试验
假设:
立体定向消融性体部放疗 (SAbR) 可延长寡转移性肾癌 (RCC) 患者的无进展生存期,并延迟全身治疗的启动。
主要目标:
• 评估开始全身治疗的延迟时间 (TTST) 作为无进展生存期 (PFS) 的替代指标,PFS 定义为从 SAbR 的第一天到开始全身治疗的时间。
次要目标:
- 评估接受 SAbR 治疗的寡转移性肾细胞癌患者的改良无进展生存期 (mPFS)。
- 评估总生存期 (OS)
- 评估癌症特异性生存 (CSS)
- 评价照射病灶的局部控制率。
- 测量与健康相关的生活质量 (HRQOL)。
研究概览
详细说明
该研究是一项前瞻性单一机构 II 期单臂开放标签试验,评估新诊断的寡转移 RCC 患者的 SAbR。
问题陈述:
- 局部治疗 (SAbR) 能否安全地延迟全身治疗的开始?
- 由于全身治疗有明显的副作用,因此安全地延迟全身治疗的开始可以为患者带来显着的生活质量益处。
- SAbR 能否治愈真正的寡转移 RCC 患者?
主要终点:
• 开始全身治疗的时间(TTST) 定义为从SAbR 的第一天到开始全身治疗的时间。
次要终点:
- 改良的无进展生存期 (mPFS) 定义为没有发生 >3 个新转移部位、不适合 SAbR 治疗的新转移部位、总共 >6 个需要 SAbR 的转移部位、局部失败的生存间隔在 SAbR 治疗部位,或脑转移的发展。
- 总生存期
- 本地控制
- 毒性
- 人力资源生活质量
样本大小:将招募 23 名患者。
统计分析:将使用 Kaplan-Meier 方法以及 95% 置信区间估计事件发生时间。
研究类型
介入性
注册 (实际的)
23
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Texas
-
Dallas、Texas、美国、75390
- University of Texas Southwestern Medical Center
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
描述
纳入标准:
- 具有有限可测量颅外转移的转移性肾细胞癌(有限转移或寡转移,定义为≤3 个转移部位)。
- 转移性疾病的放射学证据。 CT 应在注册后 30 天内进行。
- 肾细胞癌的病理证实。
- 允许事先进行手术或放疗。
- 年龄 ≥ 18 岁。
- 有生育能力的女性和男性必须同意在研究开始前和放射治疗完成后 90 天内使用充分的避孕措施(激素或屏障避孕方法;禁欲)。 如果女性在参与这项研究时怀孕或怀疑自己怀孕,她应该立即通知她的治疗医生。
具有生育潜力的女性是指满足以下条件的任何女性(无论性取向如何,是否接受过输卵管结扎或选择保持独身):
- 没有接受过子宫切除术或双侧卵巢切除术;要么
至少连续 12 个月没有自然绝经(即,在之前连续 12 个月的任何时间有月经)。
- 能够理解并愿意签署书面知情同意书并同意接受图像研究和跟进
排除标准:
- 通过对比 MRI 或对比 CT 扫描(推荐对比)评估的脑转移受试者。
- 既往有脑转移病史的受试者。
- 在过去 1 年内接受过肾癌全身治疗的受试者,除了一种免疫或细胞因子治疗(例如 之前的 IL-2);其他癌症的全身治疗不适用于此排除标准
- 具有 ≥ 3 个由 Motzer 等人定义的不良预后因素的受试者。 (1999), (KPS 1, Hgb < LLN, LDH >1.5x normal, corrected serum calcium >10mg/dl and about prior nephrectomy), 具有 0、1-2 和 ≥ 3 个因素的患者死亡时间为 20个月、10 个月和 4 个月。
- 预期寿命<6个月的受试者。
- 接受任何其他研究药物的受试者
- 由于先天性异常的可能性以及该方案可能伤害哺乳婴儿的可能性,受试者不得怀孕。
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:立体定向消融体辐射 (SABR)
对所有可测量转移部位(≤3)的立体定向消融体放射 (SAbR) 将通过 SAbR 进行治疗。
如果具有 SAbR 的内科和放射肿瘤学家都认为合适,将评估新的转移部位以继续治疗。
|
SAbR 治疗方案包括≥25Gy x1 分次、≥12Gy x 3 分次或≥8Gy x 5 分次。
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percentage of Participants With Delay in Time to Start of Systemic Therapy (TTST)
大体时间:1 Year
|
The percentage of participants with more than 1 year time to systemic therapy (TTST) will be reported for this outcome.
Initiation of systemic therapy >1 year (delay in time) is a surrogate of progression free survival (PFS) and is defined as the time from the first day of SAbR to start of systemic therapy.
|
1 Year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Modified Progression-free Survival (mPFS) for Patients Who Are Treated With SAbR
大体时间:5.7 years
|
Modified progression-free survival (mPFS) for patients with oligometastatic renal cell carcinoma who are treated with SAbR.
Modified progression-free survival (mPFS) is defined as the survival interval without development of >3 sites of new metastasis, new sites of metastases that are not amenable to SAbR treatment, a total of >6 sites of metastasis that required SAbR, local failure at SAbR-treated site, or development of brain metastasis, with the definition of new metastasis and local failure (progression) as defined by RECIST.
"Metastasis" in this entire protocol refers to extra-cranial metastasis unless otherwise specified.
|
5.7 years
|
|
Progression-free Survival on Systemic Therapy (PFS-ST)
大体时间:5.7 years
|
To evaluate progression on next line of systemic therapy as defined by RECIST 1.1 starting from mPFS (modified progression free survival).
Response and progression will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST v 1.1) Committee [Eur J Cancer.
2009;45(2):228-247].
Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in the RECIST v1.1 criteria.
|
5.7 years
|
|
Overall Survival (OS)
大体时间:5.7 years
|
Overall survival (OS), which is defined as the time between date of registration and the date of death due to any cause.
|
5.7 years
|
|
Cancer Specific Survival (CSS)
大体时间:5.7 years
|
Cancer specific survival is defined as the time between date of registration and the date of death due to renal cell carcinoma.
|
5.7 years
|
|
Local Control
大体时间:5.7 years
|
Radiographic progression with >30% increase in the longest diameter of the treated lesions.
|
5.7 years
|
|
Median Response Duration
大体时间:1.8 years
|
Median response duration is defined as the time between the date a response (CR or PR) was first seen until date of progression.
Response and progression will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST v 1.1) Committee [Eur J Cancer.
2009;45(2):228-247].
Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in the RECIST v1.1 criteria.
|
1.8 years
|
|
Time to Development of New Lesions
大体时间:5.7 years
|
Interval time to development of new lesions that can be treated with additional local therapy- title would be this or a shortened version of it.
Time to event will be estimated using the Kaplan-Meier approach along with the 95% confidence interval.
|
5.7 years
|
|
Time to Disease Progression That Cannot be Treated
大体时间:5.7 years
|
To measure the time interval from registration to time to disease progression that cannot be treated with further local therapy and need to initiate or switch systemic therapy.
Time to event will be estimated using the Kaplan-Meier approach along with the 95% confidence interval.
|
5.7 years
|
|
Toxicity Measurement
大体时间:5.7years
|
Severity or Toxicity will be assessed according to the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE), version 5.0.
Events have been counted if they are considered related to the investigational intervention included "possible," "probable," and "definite."
To ensure transparency, all AEs with "unlikely" or greater attribution are included.
|
5.7years
|
|
Change in Health-related Quality of Life (HRQOL) FACT-G
大体时间:[Baseline-3mon (months)];(Baseline-9mon.);(Baseline-15mon.); (Baseline-21mon.);(Baseline-27mon.);(Baseline-33mon.)
|
HRQOL will be measured using FACT-G questionnaire responses from baseline to certain time points (3, 9, 15,21,27,33 months) until the completion of follow ups.
FACT-G is a measure that sums the functional wellbeing (FWB), physical wellbeing (PWB), the social/family well-being (S/FWB), and emotional wellbeing (EMB).FACT-G total score range (0-108); Higher values indicate a better HRQOL.
|
[Baseline-3mon (months)];(Baseline-9mon.);(Baseline-15mon.); (Baseline-21mon.);(Baseline-27mon.);(Baseline-33mon.)
|
|
Change in Health-related Quality of Life (HRQOL) EQ-VAS
大体时间:[Baseline-3mon (months)];(Baseline-9mon.);(Baseline-15mon.); (Baseline-21mon.);(Baseline-27mon.);(Baseline-33mon.)
|
HRQOL will be measured using EQ-VAS (EuroQol- Visual analog scale) questionnaire at baseline and at specific timepoints (3,9,15,21,27,33 months) until the completion of follow ups.
The EQ-VAS is a global measure of patient perception of their health ranging from 0-100, with 0 being the worst health they can imagine, and 100 being the best health they can imagine.
|
[Baseline-3mon (months)];(Baseline-9mon.);(Baseline-15mon.); (Baseline-21mon.);(Baseline-27mon.);(Baseline-33mon.)
|
|
Change in Health-related Quality of Life (HRQOL) EQ-5D at 3 Months
大体时间:Baseline, 3months
|
HRQOL will be measured using EQ-5D (EuroQol- 5 Dimension) questionnaire at baseline and at certain specific timepoints (3,9,15,21,27,33 months) until the completion of follow ups.
EQ-5D-5L is a self-assessed, health related, quality of life questionnaire.
The scale measures quality of life on a 5-component scale including the domains - mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
|
Baseline, 3months
|
|
Change in Health-related Quality of Life (HRQOL) EQ-5D at 9 Months
大体时间:Baseline, 9 months
|
HRQOL will be measured using EQ-5D (EuroQol- 5 Dimension) questionnaire at baseline and at certain specific timepoints (3,9,15,21,27,33 months) until the completion of follow ups.
EQ-5D-5L is a self-assessed, health related, quality of life questionnaire.
The scale measures quality of life on a 5-component scale including the domains - mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
|
Baseline, 9 months
|
|
Change in Health-related Quality of Life (HRQOL) EQ-5D at 15 Months
大体时间:Baseline, 15 months
|
HRQOL will be measured using EQ-5D (EuroQol- 5 Dimension) questionnaire at baseline and at certain specific timepoints (3,9,15,21,27,33 months) until the completion of follow ups.
EQ-5D-5L is a self-assessed, health related, quality of life questionnaire.
The scale measures quality of life on a 5-component scale including the domains - mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
|
Baseline, 15 months
|
|
Change in Health-related Quality of Life (HRQOL) EQ-5D at 21 Months
大体时间:Baseline, 21 months
|
HRQOL will be measured using EQ-5D (EuroQol- 5 Dimension) questionnaire at baseline and at certain specific timepoints (3,9,15,21,27,33 months) until the completion of follow ups.
EQ-5D-5L is a self-assessed, health related, quality of life questionnaire.
The scale measures quality of life on a 5-component scale including the domains - mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
|
Baseline, 21 months
|
|
Change in Health-related Quality of Life (HRQOL) EQ-5D at 27 Months
大体时间:Baseline, 27 months
|
HRQOL will be measured using EQ-5D (EuroQol- 5 Dimension) questionnaire at baseline and at certain specific timepoints (3,9,15,21,27,33 months) until the completion of follow ups.
EQ-5D-5L is a self-assessed, health related, quality of life questionnaire.
The scale measures quality of life on a 5-component scale including the domains - mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
|
Baseline, 27 months
|
|
Change in Health-related Quality of Life (HRQOL) EQ-5D at 33 Months
大体时间:Baseline, 33 months
|
HRQOL will be measured using EQ-5D (EuroQol- 5 Dimension) questionnaire at baseline and at certain specific timepoints (3,9,15,21,27,33 months) until the completion of follow ups.
EQ-5D-5L is a self-assessed, health related, quality of life questionnaire.
The scale measures quality of life on a 5-component scale including the domains - mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
|
Baseline, 33 months
|
|
Change in Health-related Quality of Life (HRQOL) FKSI
大体时间:[Baseline-3mon (months)];(Baseline-9mon.);(Baseline-15mon.); (Baseline-21mon.);(Baseline-27mon.);(Baseline-33mon.)
|
HRQOL will be measured using FKSI questionnaire at baseline and at certain specific timepoints (3,9,15,21,27,33 months) until the completion of follow ups.
FKSI adds to the FACT-G (27 items) by including 15 items specific to kidney cancer patients.
FKSI is a questionnaire for FACT-Kidney Symptom Index used to assess QoL/participant-reported outcomes for participants diagnosed with renal cell cancer.
The FKSI contained 15 questions each ranging from 0 (not at all) to 4 (very much) so that FKSI ranged between 0-60 where higher scores reflects better functioning and fewer symptoms.
|
[Baseline-3mon (months)];(Baseline-9mon.);(Baseline-15mon.); (Baseline-21mon.);(Baseline-27mon.);(Baseline-33mon.)
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Health-related Quality of Life (HRQOL) Cost-effectiveness
大体时间:Baseline [After Protocol Modification], at 3M (months) [Prior to Protocol Modification]
|
Health care utilization data needed to assess costs will be obtained from the cost & convenience questionnaire, which includes costs of hospitalization, treatment, ER visits, physician and clinic visits and medications.
Markov modeling with probabilistic sensitivity analysis will be used to correlate quality-adjusted survival and cost.
Cost-effective analysis (cost & convenience questionnaire) will be given prior to treatment and at the time of progression.
|
Baseline [After Protocol Modification], at 3M (months) [Prior to Protocol Modification]
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Raquibul Hannan, MD, PhD、University of Texas
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2018年7月19日
初级完成 (实际的)
2024年1月24日
研究完成 (实际的)
2024年1月24日
研究注册日期
首次提交
2016年10月26日
首先提交符合 QC 标准的
2016年11月3日
首次发布 (估计的)
2016年11月7日
研究记录更新
最后更新发布 (实际的)
2026年8月31日
上次提交的符合 QC 标准的更新
2026年8月7日
最后验证
2026年8月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- STU 042016-046
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
是的
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.